Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer.
Journal: Research square
Published: June 05, 2026
Convergent IGF2 overexpression in pheochromocytoma/paraganglioma: insights from Beckwith-Wiedemann syndrome.
Journal: Endocrine-related cancer
Published: February 03, 2026
Alternatively activated monocyte-derived myeloid cells promote extracellular pathogen persistence in pulmonary fungal granulomas.
Journal: The Journal of experimental medicine
Published: February 02, 2026
Expansion of Germline Variants in Primary Hyperparathyroidism: Fumarate Hydratase Deficiency as a Cause of Parathyroid Adenomas.
Journal: Endocrine pathology
Published: January 27, 2026
Spatial and Bulk Transcriptomics Reveal Distinct Molecular Signatures in Kaposi Sarcoma with and Without other KSHV-Associated Diseases.
Journal: medRxiv : the preprint server for health sciences
Published: December 18, 2025
Spatial and bulk transcriptomics reveal distinct molecular signatures in Kaposi sarcoma with and without other KSHV-associated diseases.
Journal: Journal of translational medicine
Published: December 08, 2025
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions.
Journal: The American journal of surgical pathology
Published: October 17, 2025
Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: October 03, 2025
RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 07, 2025
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 22, 2025
MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration.
Journal: NPJ precision oncology
Published: June 29, 2025
Last Updated: 09/26/2026